Sensimed S.A., a Lausanne, Switzerland-based medtech company, has received a CHF3.5m equity financing from New Value AG (SIX: NEWN).
Founded in 2003 as a spin-off of EPFL, the company’s first approved product – SENSIMED Triggerfish(R) – allows a continuous monitoring of the intra-ocular pressure, which is one of the main risk factors for the development of glaucoma.
The funds, which will be used to achieve approval in the US and in Asian countries, to commercialize the device in selected geographies, to run post-marketing application trials and to fund ongoing operations, are part of a series B financing.
Existing investors in Sensimed include Wellington Partners, Vinci Capital and BlueOcean Ventures, which closed the first part of the series B round with CHF10m in Mai 2010.
In addition, strategic and private investors joined.